Airsculpt Technologies Inc (AIRS)vsJohnson & Johnson (JNJ)
AIRS
Airsculpt Technologies Inc
$5.11
-10.51%
HEALTHCARE · Cap: $382.36M
JNJ
Johnson & Johnson
$232.77
+1.07%
HEALTHCARE · Cap: $536.54B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 63365% more annual revenue ($96.36B vs $151.84M). JNJ leads profitability with a 21.8% profit margin vs -7.4%. JNJ earns a higher WallStSmart Score of 59/100 (C).
AIRS
Avoid34
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.7%
Fair Value
$2.40
Current Price
$5.11
$2.71 discount
Margin of Safety
-71.4%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 200.0% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -11.2% — below average capital efficiency
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : AIRS
The strongest argument for AIRS centers on EPS Growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : AIRS
The primary concerns for AIRS are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
AIRS profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
AIRS carries more volatility with a beta of 2.02 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 34/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Airsculpt Technologies Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Airsculpt Technologies Inc (AIRS) is a pioneering company in the aesthetic medical technology sector, renowned for its innovative AirSculpt® procedure that delivers minimally invasive body contouring with a strong commitment to patient safety and comfort. The company is strategically expanding its network of licensed practitioners, supported by a robust focus on technological advancements, which positions Airsculpt favorably within the rapidly growing non-invasive cosmetic treatment market. As consumer demand for aesthetic solutions continues to rise globally, Airsculpt is well-positioned to enhance its market share and diversify its service offerings, aiming to achieve substantial growth and sustainable value for its investors.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?